Associated Papers
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A et al.
Journal for Immunotherapy of Cancer, 2020
Select a paper to view details